Tildrakizumab: First Global Approval
- 11 May 2018
- journal article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 78 (8), 845-849
- https://doi.org/10.1007/s40265-018-0917-3
Abstract
Merck & Company Inc. have developed tildrakizumab (tildrakizumab-asmn; Ilumya™), a high-affinity, humanised IgG1 κ monoclonal antibody that specifically targets interleukin-23 p19, as a treatment for chronic plaque psoriasis. The drug was recently approved for marketing by the US FDA based on positive results from the phase III reSURFACE clinical trial programme in patients with chronic plaque psoriasis. This article summarizes the milestones in the development of tildrakizumab leading to this first approval for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.Keywords
This publication has 5 references indexed in Scilit:
- Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy SubjectsBasic & Clinical Pharmacology & Toxicology, 2018
- Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical StudiesSKIN The Journal of Cutaneous Medicine, 2018
- Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque PsoriasisSKIN The Journal of Cutaneous Medicine, 2018
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsThe Lancet, 2017
- Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trialBritish Journal of Dermatology, 2015